Fulgent Genetics, Inc. (NASDAQ: FLGT) is a Healthcare company (Medical - Diagnostics & Research) with a market capitalization of $676M. The Maz Rating grades it against the other companies in its sector.
Fulgent Genetics, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $24.21, Fulgent Genetics, Inc. trades at 2.0x sales and 0.7x book value. Over the last twelve months it generated about $332M of revenue and a net loss of $87M. It runs a gross margin of 33.8%, an operating margin of -38.5% and a net margin of -27.5%. It shows return on equity of -8.8%, return on invested capital of -11.7% and a free cash flow yield of -0.2%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 5.34. Over the past 52 weeks the share price ranged from $13.46 to $31.04, with a beta of 1.00.
Fulgent Genetics, Inc. does not currently pay a dividend.
9 Wall Street analyst ratings cover the stock: 6 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.